BR112012029262A2 - métodos de tratamento de infecção bacteriana recorrente - Google Patents

métodos de tratamento de infecção bacteriana recorrente

Info

Publication number
BR112012029262A2
BR112012029262A2 BR112012029262A BR112012029262A BR112012029262A2 BR 112012029262 A2 BR112012029262 A2 BR 112012029262A2 BR 112012029262 A BR112012029262 A BR 112012029262A BR 112012029262 A BR112012029262 A BR 112012029262A BR 112012029262 A2 BR112012029262 A2 BR 112012029262A2
Authority
BR
Brazil
Prior art keywords
bacterial infection
treatment methods
recurrent bacterial
recurrent
methods
Prior art date
Application number
BR112012029262A
Other languages
English (en)
Other versions
BR112012029262A8 (pt
Inventor
Sears Pamela
Gorbach Sherwood
Shue Youe-Kong
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012029262(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of BR112012029262A2 publication Critical patent/BR112012029262A2/pt
Publication of BR112012029262A8 publication Critical patent/BR112012029262A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

métodos de tratamento de infecção bacteriana recorrente. a invenção atual relata métodos de tratamento de infecção gastrointestinal recorrente(gi) do clostridium difficile em um sujeito, compreendendo administrar ao sujeito uma quantidade efetiva dos componentes da invenção atual.
BR112012029262A 2010-05-18 2011-05-18 Métodos de tratamento de infecção bacteriana recorrente BR112012029262A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592310P 2010-05-18 2010-05-18
PCT/US2011/037006 WO2011146624A2 (en) 2010-05-18 2011-05-18 Methods of treating recurring bacterial infection

Publications (2)

Publication Number Publication Date
BR112012029262A2 true BR112012029262A2 (pt) 2017-07-11
BR112012029262A8 BR112012029262A8 (pt) 2018-06-12

Family

ID=44992320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029262A BR112012029262A8 (pt) 2010-05-18 2011-05-18 Métodos de tratamento de infecção bacteriana recorrente

Country Status (9)

Country Link
US (1) US20140315838A1 (pt)
AU (1) AU2011255633B2 (pt)
BR (1) BR112012029262A8 (pt)
CA (1) CA2799531A1 (pt)
CL (1) CL2012003202A1 (pt)
CO (1) CO6670519A2 (pt)
MX (1) MX2012013372A (pt)
PE (1) PE20130308A1 (pt)
WO (1) WO2011146624A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134739B2 (ja) * 2012-01-23 2017-05-24 サンタリス ファーマシューティカルズ インコーポレイテッド ビャクダン油およびクロストリジウム感染症に関連するその使用
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
WO2011146624A2 (en) 2011-11-24
WO2011146624A9 (en) 2012-05-10
US20140315838A1 (en) 2014-10-23
CO6670519A2 (es) 2013-05-15
CL2012003202A1 (es) 2013-07-12
BR112012029262A8 (pt) 2018-06-12
CA2799531A1 (en) 2011-11-24
PE20130308A1 (es) 2013-04-06
MX2012013372A (es) 2013-05-01
AU2011255633B2 (en) 2014-09-11
AU2011255633A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201170349A1 (ru) Модуляторы mif
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
MY169328A (en) Compositions for the treatment of dry eye
EA201791850A1 (ru) Борсодержащие малые молекулы
BR112013000097A2 (pt) composições e métodos relacionados a variantes da proteína a (spa)
SG10201804809RA (en) Clostridium difficile antibodies
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
EA201491500A1 (ru) Способы лечения фиброза
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
PH12014502680A1 (en) Polysaccharide compositions and methods of use
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EA201201296A1 (ru) Способы лечения диабетических язв стопы
BR112012029262A2 (pt) métodos de tratamento de infecção bacteriana recorrente
CO6670518A2 (es) Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
UA117672C2 (uk) Антибактеріальні сполуки
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
BR112012025703A2 (pt) métodos e composições para o tratamento de síndrome de intestino irritável

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: OPTIMER PHARMACEUTICALS LLC (US)

B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME CORP (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.